Erratum to “Vastatin, an Endogenous Antiangiogenesis Polypeptide That Is Lost in Hepatocellular Carcinoma, Effectively Inhibits Tumor Metastasis” (Molecular Therapy (2016) 24(8) (1358–1368)(S1525001616335870)(10.1038/mt.2016.56));Vastatin, an Endogenous Antiangiogenesis Polypeptide That Is Lost in Hepatocellular Carcinoma, Effectively Inhibits Tumor Metastasis

Molecular Therapy

Volumn 24, Issue 8, 2016, Pages 1358-1368

  Shen, Zan ^a   Yao, Chen ^a   Wang, Zifeng ^b   Yue, Lu ^c   Fang, Zheping ^d   Yao, Hong ^e   Lin, Feng ^a   Zhao, Hui ^a   Sun, Yuan Jue ^a   Bian, Xiu Wu ^a   Jiang, Wenqi ^f   Wang, Xiaomei ^g   Li, Yi ^h   Lu, Gang ^h   Poon, Wai Sang ^h   Kung, Hsiang Fu ^c   Lin, Marie Chia Mi ^g  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c QINGDAO UNIVERSITY   (China)

^d WENZHOU MEDICAL UNIVERSITY   (China)

^e XUZHOU MEDICAL UNIVERSITY   (China)

^f Cancer Center   (China)

^g Shenzhen University School of Medicine   (China)

^h CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; GLUCOSE; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NOTCH RECEPTOR; PROTEIN C FOS; TRANSCRIPTION FACTOR AP 1; ANGIOGENESIS INHIBITOR; COLLAGEN TYPE 8;

ABHD5 GENE; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOINFORMATICS; CANCER GRADING; CANCER INHIBITION; CANCER SURVIVAL; CAPILLARY DENSITY; CELL METABOLISM; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; GENE; GENE EXPRESSION REGULATION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; MALE; METASTASIS INHIBITION; MIDDLE AGED; MOUSE; NONHUMAN; OVERALL SURVIVAL; PCK1 GENE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PTPLB GENE; RAT; RBPMS GENE; SIGNAL TRANSDUCTION; SURVIVAL TIME; THROMBOCYTE; TUMOR NECROSIS; TUMOR VOLUME; UPREGULATION; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING; ADMINISTRATION AND DOSAGE; AGED; ANIMAL; DEPENDOPARVOVIRUS; DISEASE MODEL; DRUG SCREENING; ENDOTHELIUM CELL; GENE EXPRESSION; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; LIVER TUMOR; METABOLISM; METASTASIS; NECROSIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COLLAGEN TYPE VIII; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NECROSIS; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; RATS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSDUCTION, GENETIC; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84985916913     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.144     Document Type: Erratum

References (54)

1. Sherman, M (2010). Epidemiology of hepatocellular carcinoma. Oncology 78 Suppl 1: 7-10.
2. Hou, YB, Chen, MH, Yan, K, Wu, JY and Yang, W (2009). Adjuvant percutaneous radiofrequency ablation of feeding artery of hepatocellular carcinoma before treatment. World J Gastroenterol 15: 2638-2643.
3. Biolato, M, Marrone, G, Racco, S, Di Stasi, C, Miele, L, Gasbarrini, G et al. (2010). Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins Eur Rev Med Pharmacol Sci 14: 356-362.
4. Ueda, H, Fukuchi, H and Tanaka, C (2012). Toxicity and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (Review). Oncol Lett 3: 259-263.
5. Zeng, W, Gouw, AS, van den Heuvel, MC, Zwiers, PJ, Zondervan, PE, Poppema, S et al. (2008). The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization. Hepatology 48: 1517-1527.
6. Poon, RT, Ng, IO, Lau, C, Yu, WC, Yang, ZF, Fan, ST et al. (2002). Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 20: 1775-1785.
7. Takino, J, Yamagishi, S and Takeuchi, M (2012). Glycer-AGEs-RAGE signaling enhances the angiogenic potential of hepatocellular carcinoma by upregulating VEGF expression. World J Gastroenterol 18: 1781-1788.
8. Kong, J, Kong, L, Kong, J, Ke, S, Gao, J, Ding, X et al. (2012). After insufficient radiofrequency ablation, tumor-associated endothelial cells exhibit enhanced angiogenesis and promote invasiveness of residual hepatocellular carcinoma. J Transl Med 10: 230.
9. Kubota, Y (2012). Tumor angiogenesis and anti-angiogenic therapy. Keio J Med 61: 47-56.
10. Hoang, T, Huang, S, Armstrong, E, Eickhoff, JC and Harari, PM (2012). Enhancement of radiation response with bevacizumab. J Exp Clin Cancer Res 31: 37.
11. Lai, SL, Cheah, SC, Wong, PF, Noor, SM and Mustafa, MR (2012). In vitro and in vivo anti-angiogenic activities of Panduratin A. PLoS ONE 7: e38103.
12. Jayson, GC, Hicklin, DJ and Ellis, LM (2012). Antiangiogenic therapy-evolving view based on clinical trial results. Nat Rev Clin Oncol 9: 297-303.
13. Bergers, G and Hanahan, D (2008). Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603.
14. Xu, R, Yao, ZY, Xin, L, Zhang, Q, Li, TP and Gan, RB (2001). NC1 domain of human type VIII collagen (alpha 1) inhibits bovine aortic endothelial cell proliferation and causes cell apoptosis. Biochem Biophys Res Commun 289: 264-268.
15. Piwnica, D, Fernandez, I, Binart, N, Touraine, P, Kelly, PA and Goffin, V (2006). A new mechanism for prolactin processing into 16K PRL by secreted cathepsin D. Mol Endocrinol 20: 3263-3278.
16. Genersch, E, Hayess, K, Neuenfeld, Y and Haller, H (2000). Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: involvement of Ras-dependent and-independent pathways. J Cell Sci 113 Pt 23: 4319-4330.
17. Ortega, N and Werb, Z (2002). New functional roles for non-collagenous domains of basement membrane collagens. J Cell Sci 115(Pt 22): 4201-4214.
18. Mott, JD and Werb, Z (2004). Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16: 558-564.
19. Kvansakul, M, Bogin, O, Hohenester, E and Yayon, A (2003). Crystal structure of the collagen alpha1(VIII) NC1 trimer. Matrix Biol 22: 145-152.
20. Hopfer, U, Fukai, N, Hopfer, H, Wolf, G, Joyce, N, Li, E et al. (2005). Targeted disruption of Col8a1 and Col8a2 genes in mice leads to anterior segment abnormalities in the eye. FASEB J 19: 1232-1244.
21. Adiguzel, E, Hou, G, Mulholland, D, Hopfer, U, Fukai, N, Olsen, B et al. (2006). Migration and growth are attenuated in vascular smooth muscle cells with type VIII collagen-null alleles. Arterioscler Thromb Vasc Biol 26: 56-61.
22. Lopes, J, Adiguzel, E, Gu, S, Liu, SL, Hou, G, Heximer, S et al. (2013). Type VIII collagen mediates vessel wall remodeling after arterial injury and fibrous cap formation in atherosclerosis. Am J Pathol 182: 2241-2253.
23. Adiguzel, E, Hou, G, Sabatini, PJ and Bendeck, MP (2013). Type VIII collagen signals via ß1 integrin and RhoA to regulate MMP-2 expression and smooth muscle cell migration. Matrix Biol 32: 332-341.
24. Ribatti, D (2009). Endogenous inhibitors of angiogenesis A historical review. Leukemia Res 33: 638-644.
25. Thomas, JP, Arzoomanian, RZ, Alberti, D, Marnocha, R, Lee, F, Friedl, A et al. (2003). Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 21: 223-231.
26. O'Reilly, MS, Boehm, T, Shing, Y, Fukai, N, Vasios, G, Lane, WS et al. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285.
27. Herbst, RS, Hess, KR, Tran, HT, Tseng, JE, Mullani, NA, Charnsangavej, C et al. (2002). Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20: 3792-3803.
28. Musso, O, Rehn, M, Théret, N, Turlin, B, Bioulac-Sage, P, Lotrian, D et al. (2001). Tumor progression is associated with a significant decrease in the expression of the endostatin precursor collagen XVIII in human hepatocellular carcinomas. Cancer Res 61: 45-49.
29. Zhang, L, Shen, X, Lu, Q, Zhou, Q, Gu, J, Gan, R et al. (2012). A potential therapeutic strategy for inhibition of ocular neovascularization with a new endogenous protein: rhEDI-8t. Graefes Arch Clin Exp Ophthalmol 250: 731-739.
30. Ge, W, Cao, DD, Wang, HM, Jie, FF, Zheng, YF and Chen, Y (2011). Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis. Asian Pac J Cancer Prev 12: 2901-2907.
31. Dhanabal, M, Volk, R, Ramchandran, R, Simons, M and Sukhatme, VP (1999). Cloning, expression, and in vitro activity of human endostatin. Biochem Biophys Res Commun 258: 345-352.
32. Hanai, J, Dhanabal, M, Karumanchi, SA, Albanese, C, Waterman, M, Chan, B et al. (2002). Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem 277: 16464-16469.
33. Kim, YM, Hwang, S, Kim, YM, Pyun, BJ, Kim, TY, Lee, ST et al. (2002). Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 277: 27872-27879.
34. Dixelius, J, Cross, M, Matsumoto, T, Sasaki, T, Timpl, R and Claesson-Welsh, L (2002). Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res 62: 1944-1947.
35. Kim, YM, Jang, JW, Lee, OH, Yeon, J, Choi, EY, Kim, KW et al. (2000). Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 60: 5410-5413.
36. Chaves, KC, Peron, JP, Chammas, R, Turaca, LT, Pesquero, JB, Braga, MS et al. (2012). Endostatin gene therapy stimulates upregulation of ICAM-1 and VCAM-1 in a metastatic renal cell carcinoma model. Cancer Gene Ther 19: 558-565.
37. Colorado, PC, Torre, A, Kamphaus, G, Maeshima, Y, Hopfer, H, Takahashi, K et al. (2000). Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 60: 2520-2526.
38. Tandle, A, Blazer, DG 3rd and Libutti, SK (2004). Antiangiogenic gene therapy of cancer: recent developments. J Transl Med 2: 22.
39. Marconcini, L, Marchio, S, Morbidelli, L, Cartocci, E, Albini, A, Ziche, M et al. (1999). c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc Natl Acad Sci USA 96: 9671-9676.
40. Hübscher, SG and Strain, AJ (2005). Another Notch to be added to the list of hepatocellular growth regulatory factors Hepatology 41: 439-442.
41. Houde, C, Li, Y, Song, L, Barton, K, Zhang, Q, Godwin, J et al. (2004). Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 104: 3697-3704.
42. Chien, MH, Ku, CC, Johansson, G, Chen, MW, Hsiao, M, Su, JL et al. (2009). Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. Carcinogenesis 30: 2005-2013.
43. O'Neil, JD, Owen, TJ, Wood, VH, Date, KL, Valentine, R, Chukwuma, MB et al. (2008). Epstein-Barr virus-encoded EBNA1 modulates the AP-1 transcription factor pathway in nasopharyngeal carcinoma cells and enhances angiogenesis in vitro. J Gen Virol 89(Pt 11): 2833-2842.
44. Singh, NK, Van Quyen, D, Kundumani-Sridharan, V, Brooks, PC and Rao, GN (2010). AP-1 (Fra-1/c-Jun)-mediated induction of expression of matrix metalloproteinase-2 is required for 15(S)-hydroxyeicosatetraenoic acid-induced angiogenesis. J Biological Chem 285: 16830-16843.
45. Beverly, A, Teicher, WML and Helman, LJ (2012). Targeting cancer metabolism. Clin Cancer Res 18: 5537-5545.
46. Beale, EG, Harvey, BJ and Forest, C (2007). PCK1 and PCK2 as candidate diabetes and obesity genes. Cell Biochem Biophys 48: 89-95.
47. Millward, CA, Desantis, D, Hsieh, CW, Heaney, JD, Pisano, S, Olswang, Y et al. (2010). Phosphoenolpyruvate carboxykinase (Pck1) helps regulate the triglyceride/fatty acid cycle and development of insulin resistance in mice. J Lipid Res 51: 1452-1463.
48. Granneman, JG, Moore, HP, Mottillo, EP and Zhu, Z (2009). Functional interactions between Mldp (LSDP5) and Abhd5 in the control of intracellular lipid accumulation. J Biol Chem 284: 3049-3057.
49. Kwong, JM, Quan, A, Kyung, H, Piri, N and Caprioli, J (2011). Quantitative analysis of retinal ganglion cell survival with Rbpms immunolabeling in animal models of optic neuropathies. Invest Ophthalmol Vis Sci 52: 9694-9702.
50. Shen, Z, Yang, ZF, Gao, Y, Li, JC, Chen, HX, Liu, CC et al. (2008). The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma. Cancer Res 68: 404-414.
51. Lum, CT, Yang, ZF, Li, HY, Wai-Yin Sun, R, Fan, ST, Poon, RT et al. (2006). Gold(III) compound is a novel chemocytotoxic agent for hepatocellular carcinoma. Int J Cancer 118: 1527-1538.
52. Antigny, F, Girardin, N and Frieden, M (2012). Transient receptor potential canonical channels are required for in vitro endothelial tube formation. J Biol Chem 287: 5917-5927.
53. Weidner, N (1995). Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36: 169-180.
54. Tanigawa, N, Lu, C, Mitsui, T and Miura, S (1997). Quantitation of sinusoid-like vessels in hepatocellular carcinoma: its clinical and prognostic significance. Hepatology 26: 1216-1223.